It prevents the virus from entering human cells as well as preventing it from reproducing. Vapendavir is currently in advanced clinical trials for the treatment of rhinovirus infections in people ...

Results from the VirTus Respiratory Research Ltd Human Rhinovirus Challenge Model Used to Advance Altesa BioSciences’ Lead Medicine into Advanced Clinical Trials S tudy conducted by VirTus ...

Study details Altesa's rhinovirus challenge study was conducted by VirTus Respiratory Research Ltd. in London, United Kingdom, co-led by Professor Sebastian Johnston and Dr. Michael Edwards.

It prevents the virus from entering human cells as well as preventing it from reproducing. Vapendavir is currently in advanced clinical trials for the treatment of rhinovirus infections in people ...

Rhinoviruses, coronaviruses and respiratory syncytial virus (RSV) are often to blame. But before these pathogens began to spread between people, humans probably acquired them from other vertebrates.

Add in all the C rhinovirus types (more than 50), then cram in RSV’s virus types (more than 40), and that same vaccine would have to be packed with more than 200 strains.

A capsid-binding drug, Vapendavir was acquired by Vaxart in 2018 during a merger with Aviragen Therapeutics. ... The drug showed activity against a broad spectrum of enteroviruses, along with the ...